GW2580 is an orally bioavailable inhibitor of cFMS kinase. GW2580 was found to completely inhibit human cFMS kinase in vitro at 0.06 microM and was inactive against 26 other kinases. GW2580 at 1 microM completely inhibited CSF-1-induced growth of mouse M-NFS-60 myeloid cells and human monocytes and completely inhibited bone degradation in cultures of human osteoclasts, rat calvaria, and rat fetal long bone. After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 production in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection.
CSF-1R Inhibitors Related Products:
Pazopanib; Pazopanib HCl; Linifanib; ENMD-2076; ENMD-2076 Tartrate; OSI-930; Agerafenib; Ki20227; PLX5622; Pexidartinib; Pexidartinib HCL; Aprepitant; Erdafitinib; BLZ945